Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TET2 | Q6N021 | 6/20 | 0.40 |
| ▸ | KDM4A | O75164 | 2/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.40 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.40 |
| ▸ | TET3 | O43151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.34 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.33 |
| ▸ | BHMT | Q93088 | 4/20 | 0.32 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL721101 | 0.79 | GPR84 (0.50) | TET2KDM4AKDM4CKDM2ATET3 | |
| SCHEMBL3435788 | 0.78 | BHMT (0.55) | BHMTBHMT2 | |
| SCHEMBL15285691 | 0.78 | BHMT (0.55) | BHMTBHMT2 | |
| SCHEMBL10639397 | 0.78 | GABRR1 (0.42) | SMN1; SMN2ALOX5BHMTBHMT2 | |
| SCHEMBL15285694 | 0.78 | BHMT (0.55) | BHMTBHMT2 | |
| SCHEMBL32674538 | 0.78 | ALOX5 (0.33) | SMN1; SMN2ALOX5 | |
| Malic Acid SCHEMBL11198944 | 0.75 | SMN1; SMN2 (0.48) | TET2TET3SMN1; SMN2ALOX5TET1 | |
| Malic Acid SCHEMBL11198947 | 0.75 | SMN1; SMN2 (0.48) | TET2TET3SMN1; SMN2ALOX5TET1 | |
| SCHEMBL10636270 | 0.73 | SLC1A3 (0.41) | SMN1; SMN2ALOX5BHMTBHMT2 | |
| SCHEMBL27028961 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3257969-B1 | ETCHING LIQUID AND ETCHING METHOD | MEC CO LTD (JP) | 2020-04-22 | — | — | EP | claimed |
| JP-6316557-A | — | — | None | — | — | JP | disclosed |
| EP-3257969-B1 | ETCHING LIQUID AND ETCHING METHOD | MEC CO LTD (JP) | 2020-04-22 | — | — | EP | disclosed |
| US-20200109475-A1 | ETCHING METHOD | MEC COMPANY LTD. (JP) | 2020-04-09 | — | — | US | disclosed |
| US-10358663-B2 | Method of production of 2,4-dihydroxybutyric acid | ADISSEO FRANCE S.A.S. (FR) | 2019-07-23 | — | — | US | disclosed |
| US-20180044801-A1 | ETCHING LIQUID AND ETCHING METHOD | MEC CO LTD (JP) | 2018-02-15 | — | — | US | disclosed |
| EP-3257969-A1 | ETCHING LIQUID AND ETCHING METHOD | MEC COMPANY LTD. (JP) | 2017-12-20 | — | — | EP | disclosed |
| EP-2633038-B1 | A METHOD OF PRODUCTION OF 2,4-DIHYDROBUTYRIC ACID | ADISSEO FRANCE SAS (FR) | 2017-04-05 | — | — | EP | disclosed |
| US-20160153013-A1 | METHOD OF PRODUCTION OF 2,4-DIHYDROXYBUTYRIC ACID | ADISSEO FRANCE SAS (FR) | 2016-06-02 | — | — | US | disclosed |
| US-9238829-B2 | Method of production of 2,4-dihydroxybutyric acid | ADISSEO FRANCE S.A.S. (FR) | 2016-01-19 | — | — | US | disclosed |
| US-8822706-B2 | Method for preparing 2-hydroxybutyrolactone | ADISSEO FRANCE S.A.S. (FR) | 2014-09-02 | — | — | US | disclosed |
| US-20130273623-A1 | NOVEL METHOD OF PRODUCTION OF 2,4-DIHYDROXYBUTIC ACID | ADISSEO FRANCE S.A.S. (FR) | 2013-10-17 | — | — | US | disclosed |
| EP-2633038-A1 | A METHOD OF PRODUCTION OF 2,4-DIHYDROXYBUTYRIC ACID | Adisseo France S.A.S. (FR) | 2013-09-04 | — | — | EP | disclosed |
| US-20130204016-A1 | METHOD FOR PREPARING 2-HYDROXYBUTYROLACTONE | ADISSEO FRANCE S.A.S. (FR) | 2013-08-08 | — | — | US | disclosed |
| WO-2012056318-A1 | A METHOD OF PRODUCTION OF 2,4-DIHYDROXYBUTYRIC ACID | ADISSEO FRANCE S.A.S. (FR) | 2012-05-03 | — | — | WO | disclosed |
| EP-2066798-B1 | PROCESS FOR THE PREPARATION OF 2-HYDROXY CARBOXYLIC ACIDS EMPLOYING BACTERIA OF THE GENUS PSEUDOMONAS, RHODOCOCCUS OR BACILLUS | SUMITOMO CHEMICAL CO (JP) | 2010-12-29 | — | — | EP | disclosed |
| US-20090318715-A1 | Method for the Production of D,L-2-Hydroxy-4-Alkylthio Butyric Acid | EVONIK DEGUSSA GMBH (DE) | 2009-12-24 | — | — | US | disclosed |
| JP-H06316557-A | ALKYLTHIOFATTY ACID DERIVATIVE AND ITS PRODUCTION, AND AGENT FOR HEPATIC DISEASE, KIDNEY DISEASE, PANCREATIC DISEASE AND CEREBRAL DISEASE | FUJI KAGAKU KOGYO KK | 1994-11-15 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130204016-A1 | METHOD FOR PREPARING 2-HYDROXYBUTYROLACTONE | OXSR1, CBR3, OXER1 | TET2 1114/4885KDM4A 1086/4885KDM4C 959/4885 |
| US-20090318715-A1 | Method for the Production of D,L-2-Hydroxy-4-Alkylthio Butyric Acid | HSD17B12, ABAT, GABBR2 | TET2 1173/4885KDM4A 2878/4885KDM4C 2734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.